ClinicalTrials.Veeva

Menu

A Post-approval LAP-BAND® Lower Body Mass Index (LBMI) Study

A

Apollo Endosurgery

Status

Terminated

Conditions

Overweight
Obesity

Study type

Observational

Funder types

Industry

Identifiers

NCT02356614
Apollo-001

Details and patient eligibility

About

This is a post-approval, multicenter, prospective, non-randomized, open-label, clinical study to evaluate the safety and effectiveness of the LAP-BAND® AP System in a lower obese population (BMI ≥ 30 kg/m2 and < 40 kg/m2) with one or more obesity-related comorbidity up to 10 years after implantation.

The reason your study has been terminated is based on the availability of long-term safety and effectiveness data from the OSB Lead-HERo-002 study and published literature.

Full description

FDA post-approval study designed to collect prospective data in a real-world setting to evaluate long-term safety and effectiveness of the LAP BAND® System in patients with a BMI of ≥ 30 kg/m2 and < 40 kg/m2 and one or more comorbid conditions. The Apollo-001 Study is a prospective, 10 year, multicenter study of patients who have decide to undergo implantation of the LAP-BAND AP® system. Outcomes include device explants, changes in weight, comorbid condition status, device- and procedure-related AEs, and reoperations.

The LBMI study was part of the condition of approval (CoA) for the Lap-Band device. It was terminated because it was no longer required to fulfill the condition of approval for the device. Apollo was able to fulfill the condition of approval (CoA) for the Lap-Band device by using data from published literature and another recently completed study (OSB Lead-Hero-002 study) which had long-term safety and effectiveness data addressing the conditions of approval.

Enrollment

325 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. LAP-BAND® System placed in a facility in the United States
  2. BMI ≥ 30 kg/m2 and < 40 kg/m2 prior to LAP-BAND® placement
  3. Presence of 1 or more obesity-related comorbidities prior to LAP-BAND® placement
  4. Aged 18 or older

Exclusion criteria

  1. Prior bariatric surgery.
  2. Participating in another ongoing clinical study in which concomitant diagnostic or therapeutic intervention that would reasonably be expected to alter patterns of care, use of medications or the outcomes under study.
  3. Vulnerable patients or those unable to exercise free informed consent.
  4. Inability to complete the questionnaires.
  5. Patients who are addicted to alcohol and/or drugs.

Trial contacts and locations

11

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems